High probability of technical success in pivotal Phase 3 trial based on unmatched efficacy data for third-line non-small cell lung cancer (NSCLC) ...

Anktiva plus checkpoint inhibitor therapy demonstrated statistically significant immune restoration across two clinical ...

More representative trial populations and standardized subgroup reporting are needed in non–small cell lung cancer (NSCLC) research, according to a meta-analysis published in Cancers, which found no ...

Significantly more facilities prescribe single-fraction stereotactic body radiation therapy than they did 20 years ago, but a minimal number of individuals with non-small cell lung cancer actually ...

After your lung cancer is diagnosed, the doctor will run tests to find out the size of the tumor and whether the cancer has spread to other parts of the body. This process is called staging. Knowing ...

Timely initiation of targeted therapy is crucial for improving cancer outcomes and patient quality of life, especially for ...

CAN-2409 extended median overall survival to 24.5 months in NSCLC patients, surpassing standard docetaxel chemotherapy outcomes. The treatment showed a significant survival benefit in non-squamous ...

Non-small cell lung cancer (NSCLC) patients with advanced disease receiving standard of care treatment have a higher overall survival (OS) than similar patients not receiving treatment. Lung cancer is ...

The dual inhibition of PD-1 and VEGF pathways by ivonescimab aims to enhance immune response and limit tumor angiogenesis, ...

About 40% of people with non-small cell lung cancer (NSCLC)—a type of cancer that begins in the tissues of your lungs—have metastatic disease at the time of their diagnosis. Metastatic NSCLC refers to ...